Pharma Focus Asia

Ono and EVQLV Collaborate to Utilize AI-Powered Antibody Design for the Development of Novel Antibody Drugs Against Multiple Targets

Wednesday, December 20, 2023

Ono Pharmaceutical Co., Ltd., headquartered in Osaka, Japan, led by President and CEO Gyo Sagara, has recently announced a collaborative partnership with EVQLV, INC, based in Miami, Florida, USA, under the leadership of CEO Andrew Satz. This collaboration aims to develop novel antibodies targeting multiple specified therapeutic targets chosen by Ono, with the goal of advancing innovative antibody drugs.

Within the framework of the agreement, EVQLV will use its proprietary Artificial Intelligence (AI)-powered Antibody Design Engine to generate therapeutic antibody designs for the specified targets. Ono will then leverage these designs to develop potential antibodies for the creation, advancement, and commercialization of antibody drug candidates. Throughout the research phase, Ono will provide EVQLV with research funding and milestone payments based on the success of the research. Additionally, Ono will retain the option rights to exclusively and globally develop and commercialize the resulting antibody drug candidates.

Expressing enthusiasm about the collaboration, Dr. Toichi Takino, Senior Executive Officer and Executive Director of Discovery and Research at Ono, stated, “We have been actively working to create biologics, including antibody drugs, to address unmet medical needs for a wide range of diseases. We are very pleased to collaborate with EVQLV and its proprietary AI-powered Antibody Design Engine. We expect that EVQLV’s AI technology will enable us to create novel antibody candidates against multiple targets more promptly and effectively. We are committed to accelerating our efforts in antibody drug discovery and bringing innovative drugs to patients as soon as possible.”

Andrew Satz, CEO and co-founder of EVQLV, emphasized the significance of the collaboration, stating, “Ono has a successful history of identifying unique targets that have translated into life-changing medicines. At EVQLV, our mission is to make AI easily accessible to researchers to positively impact the odds of success in drug discovery. We are honored to be working alongside the scientific and drug development experts at Ono, who have the ability to leverage our AI-designed antibodies and deliver breakthrough options for patients in need.”

 

Source: ono-pharma.com

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024